Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...
Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...
Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...
Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical ...
Pfizer is a global pharmaceutical giant with an impressive portfolio of over 350 marketed medicines, 113 experimental candidates in clinical trials, and a presence in more than 200 countries.
Looking at Pfizer's recent performance in business turnaround, I think the recovery in PFE stock should continue in the medium term - the 10% total return since June 2024 may be just the beginning ...
Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The ...
Pfizer Inc (NYSE:PFE) shares are on the move Monday after activist Starboard Value acquired a $1 billion stake in the pharmaceutical giant.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback